About 14 months ago, Wuhan reported its first Covid-19 case, and soon all hell broke loose! From lockdowns to curfews and near-death experiences to close to a million lives lost to date, it’s been a nightmare. As the vaccines finally start rolling in, it’s easy to focus on all the negatives of the virus – and there have been many. But, every cloud has a silver lining, and nowhere has that been more prominent than in the Pharmaceutical industry and digital healthcare spheres.
The level of innovation in the healthcare industry over the past year or so has been exceptional. From infrastructure developments to evolving care models and the expansion of healthcare systems in developing countries, it’s a story that’ll be told for many years to come.
However, the revolutionary digital transformation remains the most significant achievement for the industry over the pandemic period. Healthcare made giant steps in digitization during Covid-19, with some experts convinced that we’re at least five years ahead of time.
The pharmaceutical industry, an integral part of healthcare, must find a way to match the success. Otherwise, all gain in the rest of healthcare could go to waste.
Hospitals and other health facilities, including small practices, are putting more money into virtual care and other remote care approaches. Indeed, according to a 2017 study by E-Consultancy, 74% of 500 healthcare and pharma industry respondents cited virtual care as one of the “most important” trends to watch. Pharma must follow suit by investing more in virtual care and telemedicine in general.